These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 12362926

  • 1. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.
    Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ.
    J Clin Pharmacol; 2002 Oct; 42(10):1116-21. PubMed ID: 12362926
    [Abstract] [Full Text] [Related]

  • 2. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD, Dane AL, Schneck DW, Warwick MJ.
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q.
    Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
    [Abstract] [Full Text] [Related]

  • 4. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
    Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW.
    J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
    [Abstract] [Full Text] [Related]

  • 5. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
    Martin PD, Warwick MJ, Dane AL, Brindley C, Short T.
    Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
    Martin PD, Warwick MJ, Dane AL, Cantarini MV.
    Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD, Mitchell PD, Schneck DW.
    Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
    [Abstract] [Full Text] [Related]

  • 8. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW.
    Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
    Li XN, Xu HR, Chen WL, Chu NN, Zhu JR.
    Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
    [Abstract] [Full Text] [Related]

  • 10. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.
    Eur J Clin Pharmacol; 2002 Nov; 58(8):527-31. PubMed ID: 12451430
    [Abstract] [Full Text] [Related]

  • 11. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
    Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E.
    Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
    [Abstract] [Full Text] [Related]

  • 12. Effect of itraconazole on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.
    Clin Pharmacol Ther; 2003 Apr; 73(4):322-9. PubMed ID: 12709722
    [Abstract] [Full Text] [Related]

  • 13. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH.
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [Abstract] [Full Text] [Related]

  • 14. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW.
    Br J Clin Pharmacol; 2003 Jan; 55(1):94-9. PubMed ID: 12534645
    [Abstract] [Full Text] [Related]

  • 15. Single-dose, 2-way crossover, bioequivalence study of two rosuvastatin formulations in normal healthy subjects under fasting conditions.
    Trabelsi F, Bartůnek A, Vlavonou R, Navrátilová L, Dubé C, Tanguay M, Hauser T.
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):741-50. PubMed ID: 22762855
    [Abstract] [Full Text] [Related]

  • 16. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
    Martin PD, Schneck DW, Dane AL, Warwick MJ.
    Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.
    Bologa R, Levine D, Parker T, Gordon B, Lanto A, Cheigh J, Stenzel K, Rubin A.
    Clin Nephrol; 2009 Dec; 72(6):437-41. PubMed ID: 19954720
    [Abstract] [Full Text] [Related]

  • 18. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
    Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW.
    J Acquir Immune Defic Syndr; 2008 Apr 15; 47(5):570-8. PubMed ID: 18176327
    [Abstract] [Full Text] [Related]

  • 19. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW.
    Clin Pharmacol Ther; 2004 Aug 15; 76(2):167-77. PubMed ID: 15289793
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
    Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ.
    Eur J Clin Pharmacol; 2003 Feb 15; 58(10):669-75. PubMed ID: 12610743
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.